Skip to Main Content

Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Conditions

Colon | Rectum

Phase II

What is the purpose of this trial?

This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for metastatic disease.

  • Trial with
    Academic GI Cancer Consortium (AGICC)
  • Start Date
    01/12/2022
  • End Date
    09/01/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    01/13/2022
  • Study HIC
    #2000026787